MDxHealth SA (MDXH) Stock Analysis
A live, multi-source view of MDxHealth SA (MDXH): real-time price, technical indicators, Wall Street analyst consensus, recent news sentiment and social buzz — aggregated into one place so you can size up the stock at a glance.
About MDxHealth SA
MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. The company's testing solutions include Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; ExoD, a non-invasive urine test to assess risk of having clinically prostate cancer; and Resolve mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection. It offers genomic prostate score, which provides personalized genomic insights to physicians and patients navigating the complexities of prostate cancer diagnosis and treatment. The company sells its products through urology sales force consisting of direct sales representatives, strategic account managers, and regional sales managers. The company has a collaboration the initiation of Genomic Prostate Score (GPS) testing. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010.
Sector: Healthcare · Industry: Diagnostics & Research · Belgium · 364 employees · mdxhealth.com
Key statistics · as of 2026-09-06
As of 2026-09-06, MDxHealth SA (MDXH) had a market capitalization of $71.4M (forward -2.0) and a beta of -501643.70; the shares traded in a 52-week range of $0.40 – $5.33 (-78.9% over the year).
- Market cap
- $71.4M
- Enterprise value
- $125.9M
- Forward P/E
- -2.0
- EPS (trailing)
- $-0.71
- EPS (forward)
- $-0.38
- Payout ratio
- 0.0%
- 52-week range
- $0.40 – $5.33
- 52-week change
- -78.9%
- Beta
- -501643.70
- Average volume
- 6.0M
- Shares outstanding
- 95.4M
- Short % of float
- 1.76%
- Profit margin
- -32.7%
Fundamental figures are recorded once every few days, dated above; they are not live and can differ from the interactive tiles.
Last universe scan · 2026-09-10
In RapidTradeView’s 2026-09-10 scan of the US universe, MDxHealth SA (MDXH) last closed at $0.69 (the last completed close before that scan).
Technicals at the scan: RSI 54 (neutral territory), price -3.9% versus its 20-day average, 20-day versus 50-day average spread +30.9%, MACD histogram -0.01.
Sentiment inputs: StockTwits 100% bullish; analyst consensus score 67/100.
Next scheduled company event: in 63 days from the scan date.
Scan values are recorded once per trading day and are not live quotes; the interactive tiles above update in real time.
Smart Money · last 90 days
Members of Congress disclosed 0 buys and 0 sells of MDXH; corporate insiders filed 1 buy and 0 sells (1 filer, latest disclosure 2026-08-17). Filings arrive days to weeks after the trade and are not a live signal. Most active filers: Mvm Partners, Llc (1B/0S). Who is trading what
RapidTradeView pick record
MDXH has not appeared in the daily picks yet. Full scoreboard
What this page covers
RapidTradeView pulls MDxHealth SA (MDXH) data from multiple independent sources and combines it into a single dashboard. Below the summary you’ll find live, interactive tiles for each of the following:
- Price & chart — real-time quote with pre/post-market moves and a line or candlestick chart.
- Technical indicators — RSI, MACD, moving averages, Bollinger Bands, volume and support/resistance, distilled into one overall signal.
- Analyst consensus — the buy/hold/sell breakdown and price targets published by Wall Street analysts.
- News sentiment — recent headlines, each scored for tone so the prevailing narrative is obvious.
- Earnings — current EPS, year-over-year change and the next scheduled earnings date.
- Social buzz — Reddit mention volume and StockTwits sentiment for the retail-trader angle.
How to read the signals
No single indicator tells the whole story. A bullish technical reading paired with a cautious analyst consensus, or strong social buzz against weak earnings, is exactly the kind of tension this view is built to surface. RapidTradeView’s signals are generated by deterministic, statistical models — they describe what the data is doing, they are not personalised recommendations to buy or sell MDXH.
Disclaimer: RapidTradeView is an educational sentiment-aggregation tool, not a licensed financial adviser, broker, or dealer. Nothing here is financial, investment, tax, or legal advice. Markets are risky and you can lose money. Always do your own research and consult a qualified professional before making any investment decision.